Skip to main content
SpringerLink
Log in

Antiangiogenetische Therapie beim Nierenzellkarzinom

Management der Nebenwirkungen

Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Mit den Tyrosinkinase-Inhibitoren Sunitinib und Sorafenib stehen 2 effektive Angiogenese-Inhibitoren zur Therapie des metastasierten Nierenzellkarzinoms zur Verfügung. Bei der notwendigen chronischen Verwendung dieser, einer neuen Substanzklasse zuzuordnenden Medikamente treten Nebenwirkungen auf, die unter Umständen eine langfristige Therapie erschweren oder verhindern können. Die meisten Nebenwirkungen lassen sich jedoch durch eine entsprechende Prophylaxe vermeiden oder erheblich abmildern, sodass diese Substanzen eingesetzt werden können. In der vorliegen Arbeit soll anhand der publizierten Daten und auf Basis der eigenen Erfahrung an 138 Patienten mit bis zu 2½ Jahren Therapiedauer eine Hilfestellung zum Nebenwirkungsmanagement gegeben werden.

Abstract

Sunitinib and Sorafenib are both effective angiogenetic inhibitors for the treatment of renal cell carcinoma. With these drugs of a new class of chronic therapy is performed. During chronic treatment, the inherent side effects may necessitate stopping the application of these drugs thus preventing the required effective therapy. Most of the effects can be avoided or attenuated by prophylaxis. In this paper the published data are reviewed and added with our experience in 138 patients over up to two and a half years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7
Abb. 8
Abb. 9

Literatur

  1. Coppin C, Porzsolt F, Awa A et al. (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev: CD001425

    Google Scholar 

  2. Escudier B, Szczylik C, Eisen T et al. (2005) Randomized phase III trial of the multi-kinase inhibitor sorafenib (Bay 43-9006) in patients with advanced RCC. ECCO Abstract

  3. Ficarra V, Artibani W (2006) Staging system of renal cell carcinoma: current issues. Eur Urol 49: 223–225

    Article  PubMed  Google Scholar 

  4. Ficarra V, Martignoni G, Galfano A et al. (2006) Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. Eur Urol 50: 786–794

    Article  PubMed  Google Scholar 

  5. Hofmann HS, Neef H, Krohe K et al. (2005) Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48: 77–81

    Article  PubMed  Google Scholar 

  6. Lang H, Lindner V, Martin M et al. (2004) Prognostic value of multifocality on progression and survival in localized renal cell carcinoma. Eur Urol 45: 749–753

    Article  PubMed  Google Scholar 

  7. Motzer RJ, Hutson TE, Tomczak P et al. (2006) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24: 930, LBA 933

    Article  Google Scholar 

  8. Motzer RJ, Michaelson MD, Redman BG et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24

    Google Scholar 

  9. Motzer RJ, Rini BI, Bukowski RM et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516–2524

    Article  PubMed  Google Scholar 

  10. Patard JJ (2006) Prognostic and biological significance of lymph node spreading in renal cell carcinoma. Eur Urol 49: 220–222

    Article  PubMed  Google Scholar 

  11. Robert C, Soria JC, Spatz A et al. (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6: 491–500

    Article  PubMed  Google Scholar 

  12. Staehler M, Haseke N, Schoppler G et al. (2006) Therapy strategies for advanced renal cell carcinoma. Urologe A 45: 99–110

    Article  PubMed  Google Scholar 

  13. Staehler M, Rohrmann K, Haseke N et al. (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 6: 835–846

    Article  PubMed  Google Scholar 

  14. Steiner T, Knels R, Schubert J (2004) Prognostic significance of tumour size in patients after tumour nephrectomy for localised renal cell carcinoma. Eur Urol 46: 327–330

    Article  PubMed  Google Scholar 

  15. Terrone C, Cracco C, Guercio S et al. (2004) Prognostic value of the involvement of the urinary collecting system in renal cell carcinoma. Eur Urol 46: 472–476

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik der Ludwig-Maximilians-Universität, Klinikum Grosshadern, Marchioninistraße 15, 81377, München, Deutschland

    M. Staehler, N. Haseke, G. Schöppler, T. Stadler & C. G. Stief

  2. Medizinische Klinik III der Ludwig-Maximilians-Universität, Klinikum Grosshadern, München, Deutschland

    G. Heinemann

Authors
  1. M. Staehler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Haseke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Schöppler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Stadler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Heinemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. G. Stief
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Staehler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Staehler, M., Haseke, N., Schöppler, G. et al. Antiangiogenetische Therapie beim Nierenzellkarzinom. Urologe 45, 1333–1344 (2006). https://doi.org/10.1007/s00120-006-1211-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-006-1211-7

Schlüsselwörter

Keywords

Search

Navigation